[go: up one dir, main page]

MX2019003397A - Metodos para tratar trastornos mitocondriales y metabolicos. - Google Patents

Metodos para tratar trastornos mitocondriales y metabolicos.

Info

Publication number
MX2019003397A
MX2019003397A MX2019003397A MX2019003397A MX2019003397A MX 2019003397 A MX2019003397 A MX 2019003397A MX 2019003397 A MX2019003397 A MX 2019003397A MX 2019003397 A MX2019003397 A MX 2019003397A MX 2019003397 A MX2019003397 A MX 2019003397A
Authority
MX
Mexico
Prior art keywords
methods
metabolic disorders
treating mitochondrial
mtor inhibitor
allosteric mtor
Prior art date
Application number
MX2019003397A
Other languages
English (en)
Other versions
MX389962B (es
Inventor
P Desai Neil
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2019003397A publication Critical patent/MX2019003397A/es
Publication of MX389962B publication Critical patent/MX389962B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para el tratamiento de enfermedades, tales como trastornos asociados a la mitocondria, por ejemplo síndrome de Leigh, MELAS, y NARP, y trastornos metabólicos, que comprenden administrar un inhibidor de mTOR alostérico, tal como una composición que comprende nanopartículas que comprenden un inhibidor de mTOR alostérico y una albúmina. También se proporcionan medicinas y kits útiles para los métodos descritos en la presente.
MX2019003397A 2016-09-28 2017-09-28 Metodos para tratar trastornos mitocondriales y metabolicos. MX389962B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662401092P 2016-09-28 2016-09-28
PCT/US2017/054149 WO2018064405A1 (en) 2016-09-28 2017-09-28 Methods of treating mitochondrial and metabolic disorders

Publications (2)

Publication Number Publication Date
MX2019003397A true MX2019003397A (es) 2019-06-06
MX389962B MX389962B (es) 2025-03-20

Family

ID=61763007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003397A MX389962B (es) 2016-09-28 2017-09-28 Metodos para tratar trastornos mitocondriales y metabolicos.

Country Status (14)

Country Link
US (1) US20190307732A1 (es)
EP (1) EP3518923A4 (es)
JP (2) JP2019529474A (es)
KR (2) KR20230003239A (es)
CN (1) CN110022876A (es)
AU (1) AU2017335902B2 (es)
BR (1) BR112019006113A2 (es)
CA (1) CA3038824A1 (es)
CL (1) CL2019000787A1 (es)
EA (1) EA201990820A1 (es)
IL (1) IL265566A (es)
MA (1) MA46365A (es)
MX (1) MX389962B (es)
WO (1) WO2018064405A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
KR20190109593A (ko) 2010-03-29 2019-09-25 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
CN116473964A (zh) 2015-06-29 2023-07-25 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
RU2020134124A (ru) * 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
WO2019226685A1 (en) * 2018-05-22 2019-11-28 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
WO2020191053A1 (en) * 2019-03-19 2020-09-24 Abraxis Bioscience, Llc Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases
AU2020375810A1 (en) 2019-10-28 2022-05-12 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN111621556A (zh) * 2019-12-31 2020-09-04 安徽医科大学第一附属医院 一种检测人线粒体atp6基因8993位点基因型的试剂盒及方法
CN111419876A (zh) * 2020-04-30 2020-07-17 复旦大学附属中山医院 线粒体移植在治疗原发性扩心病中的应用
CN112972681B (zh) * 2021-01-27 2022-06-07 西安交通大学 Mt-nd6作为新靶点在代谢综合征诊断和治疗药物中的应用
CN114848795B (zh) * 2021-02-03 2023-04-14 四川大学 RORa蛋白及其激动剂在制备抗衰老药物中的应用
CN114507677B (zh) * 2022-02-16 2023-09-05 中国人民解放军空军军医大学 Ndufs1基因在治疗心梗后心衰中的应用和相关产品

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546369A4 (en) * 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
CA2599989A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US20090029904A1 (en) * 2006-07-21 2009-01-29 Sean Oldham Compositions and methods for treatment of insulin-resistance diseases
EP2481409B1 (en) * 2007-03-07 2018-05-09 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
EP3326630A3 (en) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
ES2645692T3 (es) * 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
KR20190109593A (ko) * 2010-03-29 2019-09-25 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
WO2012149451A1 (en) * 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
US9180134B2 (en) * 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
US9962373B2 (en) * 2013-03-14 2018-05-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
JP2016537345A (ja) 2013-11-13 2016-12-01 ノバルティス アーゲー 免疫応答を増強するためのｍＴＯＲ阻害剤
WO2016134486A1 (en) 2015-02-27 2016-09-01 Steinberg Gregory Use of canagliflozin and derivatives thereof in the treatment of cancer
WO2017096270A1 (en) * 2015-12-03 2017-06-08 The Regents Of The University Of California Methods for treating mitochondrial diseases
CN109073719A (zh) * 2016-04-25 2018-12-21 皇家飞利浦有限公司 磁共振辐射屏蔽和被屏蔽的主磁体

Also Published As

Publication number Publication date
WO2018064405A1 (en) 2018-04-05
MX389962B (es) 2025-03-20
JP2019529474A (ja) 2019-10-17
CA3038824A1 (en) 2018-04-05
EA201990820A1 (ru) 2019-10-31
IL265566A (en) 2019-05-30
CL2019000787A1 (es) 2019-05-31
EP3518923A4 (en) 2020-06-17
KR20190060797A (ko) 2019-06-03
JP2022191238A (ja) 2022-12-27
BR112019006113A2 (pt) 2019-06-18
US20190307732A1 (en) 2019-10-10
KR102475256B1 (ko) 2022-12-08
AU2017335902B2 (en) 2023-08-24
EP3518923A1 (en) 2019-08-07
MA46365A (fr) 2019-08-07
AU2017335902A1 (en) 2019-04-18
CN110022876A (zh) 2019-07-16
KR20230003239A (ko) 2023-01-05

Similar Documents

Publication Publication Date Title
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
BR112017027954A2 (pt) métodos de tratamento de tumores de célula epitelioide
MX2016006025A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
CR20150571A (es) Compuestos y composiciones terapéuticos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2016004530A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2017004440A (es) Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
ECSP18002561A (es) Sales y profármacos de 1-metil-d-triptófano
CR20170157A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial